|
Subgroup analyses of patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy:Two-year clinical update. |
|
|
Honoraria - Bayer; Boehringer Ingelheim; GlaxoSmithKline; Isofol Medical; Merck Serono; Roche |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Merck Serono; Roche |
Travel, Accommodations, Expenses - Bayer; Merck Serono |
|
|
Consulting or Advisory Role - Amgen; Lilly; Merck Serono; SERVIER |
Speakers' Bureau - Bristol-Myers Squibb; Lilly; Merck Serono; Roche; Servier |
Research Funding - Amgen; Merck Serono |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Merck |
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Lilly; Roche; SERVIER |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Lilly (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bayer; Roche; SERVIER |
|
|
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; Biocartis; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; GlaxoSmithKline; Halozyme; Incyte; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; SERVIER; Sirtex Medical; Taiho Pharmaceutical |
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Baxalta; Ipsen; Novartis; Roche |
Speakers' Bureau - Sirtex Medical |
Travel, Accommodations, Expenses - MSD Oncology; Novartis |
|
|
Honoraria - Bayer; Lilly; Roche; SERVIER; Sirtex Medical |
Consulting or Advisory Role - Bayer; Lilly; Roche; SERVIER; Sirtex Medical |
Travel, Accommodations, Expenses - Roche; Sirtex Medical |
|
|
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Merck; Novartis |
Research Funding - AstraZeneca (Inst); PharmaMar |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; MERCK; tesaro |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pfizer/EMD Serono; Roche; Sanofi |
Speakers' Bureau - Novartis |
Research Funding - Merck KGaA (Inst); Novartis (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; Rafael Pharmaceuticals |
Research Funding - Advaxis (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); EMD Serono (Inst); Incyte (Inst); Lilly (Inst); Synta (Inst) |
Travel, Accommodations, Expenses - Abbvie |
|
|
Employment - Foundation Medicine (I) |
Research Funding - ARMO BioSciences; Berg Pharma; Bristol-Myers Squibb (Inst); Halozyme (Inst); HolyStone Therapeutics (Inst); Kyowa Hakko Kirin; Medivir; Novocure (Inst); Rgenix |
|
|
No Relationships to Disclose |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Gritstone Bio; Janssen; Janssen; MedImmune; Novartis; Pfizer; Pfizer; Promega; Roche/Genentech; Spectrum Pharmaceuticals |
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Roche |